HeartGenetics launches new test in Oncology

July 3, 2017

HeartGenetics continues to increase its portfolio of genetic tests, particularly within the pharmacogenetics area. OncoAlvo® is a new genetic study of the anti-EGFR antibody therapy response in metastatic colorectal carcinoma. With this new test, medical oncologists will be able to know what is the best and most effective treatment for each patient.

Check out their announcement here.

Click here to download